Proinflammatory IgG Fc structures in patients with severe COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

Presumed Asymptomatic Carrier Transmission of COVID-19

Bai, Y., Yao, L., Wei, T., Tian, F., Jin, D., Chen, L., & Wang, M. (2020) · JAMA · doi:10.1001/jama.2020.2565 · Cited by 4,496

Epidemiology of COVID-19 Among Children in China

Dong, Y., Mo, X., Hu, Y., Qi, X., Jiang, F., Jiang, Z., & Tong, S. (2020) · PEDIATRICS · doi:10.1542/peds.2020-0702 · Cited by 4,240

Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study

Bi, Q., Wu, Y., Mei, S., Ye, C., Zou, X., Zhang, Z., Liu, X., Wei, L., Truelove, S., Zhang, T., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30287-5 · Cited by 1,960

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Wilk, A. J., Rustagi, A., Zhao, N. Q., Roque, J., Martínez-Colón, G. J., McKechnie, J. L., Ivison, G. T., Ranganath, T., Vergara, R., Hollis, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0944-y · Cited by 1,493

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., So, R. T. Y., Lv, H., Mok, C. K. P., & Wilson, I. A. (2020) · Science · doi:10.1126/science.abb7269 · Cited by 1,429

Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened Among Close Contacts in Nanjing, China

Hu, Z., Song, C., Xu, C., Jin, G., Chen, Y., Xu, X., Ma, H., Chen, W., Lin, Y., Zheng, Y., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1661-4 · Cited by 1,429

Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding

Xu, Y., Li, X., Zhu, B., Liang, H., Fang, C., Gong, Y., Guo, Q., Sun, X., Zhao, D., Shen, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0817-4 · Cited by 1,415

Antibody-dependent enhancement of severe dengue disease in humans

Katzelnick, L. C., Gresh, L., Halloran, M. E., Mercado, J. C., Kuan, G. M., Gordon, A. L., Balmaseda, Á., & Harris, E. (2017) · Science · doi:10.1126/science.aan6836 · Cited by 1,202

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Wilk, A. J., Rustagi, A., Zhao, N. Q., Roque, J., Martínez-Colón, G. J., McKechnie, J. L., Ivison, G. T., Ranganath, T., Vergara, R., Hollis, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0944-y · Cited by 1,493

Immunological considerations for COVID-19 vaccine strategies

Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015

The immunology and immunopathology of COVID-19

Mérad, M., Blish, C. A., Sallusto, F., & Iwasaki, A. (2022) · Science · doi:10.1126/science.abm8108 · Cited by 780

FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation

Junqueira, C., Crespo, Â. C., Ranjbar, S., de Lacerda, L., Lewandrowski, M., Ingber, J., Parry, B. A., Ravid, S., Clark, S. A., Schrimpf, M. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04702-4 · Cited by 699

Pathological sequelae of long-haul COVID

Mehandru, S., & Mérad, M. (2022) · Nature Immunology · doi:10.1038/s41590-021-01104-y · Cited by 675

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560

Inflammasome activation in infected macrophages drives COVID-19 pathology

Sefik, E., Qu, R., Junqueira, C., Kaffe, E., Mirza, H., Zhao, J., Brewer, J. R., Han, A., Steach, H. R., Israelow, B., et al. (2022) · Nature · doi:10.1038/s41586-022-04802-1 · Cited by 543

New-onset IgG autoantibodies in hospitalized patients with COVID-19

Chang, S. E., Feng, A., Meng, W., Apostolidis, S. A., Mack, E., Artandi, M. K., Barman, L., Bennett, K., Chakraborty, S., Chang, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25509-3 · Cited by 496

Inflammasome activation at the crux of severe COVID-19

Vora, S. M., Lieberman, J., & Wu, H. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00588-x · Cited by 332

High titers and low fucosylation of early human anti–SARS-CoV-2 IgG promote inflammation by alveolar macrophages

Hoepel, W., Chen, H., Geyer, C. E., Allahverdiyeva, S., Manz, X. D., de Taeye, S. W., Aman, J., Mes, L., Steenhuis, M., Griffith, G. R., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf8654 · Cited by 282

Global absence and targeting of protective immune states in severe COVID-19

Combes, A. J., Courau, T., Kuhn, N. F., Hu, K. H., Ray, A., Chen, W. S., Chew, N. W., Cleary, S. J., Kushnoor, D., Reeder, G. C., et al. (2021) · Nature · doi:10.1038/s41586-021-03234-7 · Cited by 260

Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection

Zhang, A., Stacey, H. D., D’Agostino, M. R., Tugg, Y., Marzok, A., & Miller, M. S. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00813-1 · Cited by 225

Compromised SARS-CoV-2-specific placental antibody transfer

Atyeo, C. G., Pullen, K. M., Bordt, E. A., Fischinger, S., Burke, J. S., Michell, A. R., Slein, M. D., Loos, C., Shook, L. L., Boatin, A. A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.12.027 · Cited by 207

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

Andreano, E., Nicastri, E., Paciello, I., Pileri, P., Manganaro, N., Piccini, G., Manenti, A., Pantano, E., Kabanova, A., Troisi, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.035 · Cited by 199

Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses — are we our own worst enemy?

Wong, L.-Y. R., & Perlman, S. M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00656-2 · Cited by 202

Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19

Shaath, H., Vishnubalaji, R., Elkord, E., & Alajez, N. M. (2020) · Cells · doi:10.3390/cells9112374 · Cited by 192

Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy

Yamin, R., Jones, A., Hoffmann, H.-H., Schäfer, A., Kao, K. S., Francis, R., Sheahan, T. P., Baric, R. S., Rice, C. M., Ravetch, J. V., et al. (2021) · Nature · doi:10.1038/s41586-021-04017-w · Cited by 186

Systems serology detects functionally distinct coronavirus antibody features in children and elderly

Selva, K. J., van de Sandt, C. E., Lemke, M. M., Lee, C. Y., Shoffner, S. K., Chua, B. Y. L., Davis, S. K., Nguyen, T. H. O., Rowntree, L. C., Hensen, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22236-7 · Cited by 179

Antibody and B cell responses to SARS-CoV-2 infection and vaccination

Röltgen, K., & Boyd, S. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.009 · Cited by 143

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Jagannathan, P., Andrews, J. R., Bonilla, H. F., Hedlin, H., Jacobson, K. B., Balasubramanian, V., Purington, N., Kamble, S., de Vries, C. R., Quintero, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22177-1 · Cited by 135

Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity

Chakraborty, S., González, J. C., Sievers, B. L., Mallajosyula, V. V. A., Chakraborty, S., Dubey, M., Ashraf, U., Cheng, B. Y.-L., Kathale, N. D., Tran, K. Q. T., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm7853 · Cited by 137

mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions

Kapłonek, P., Cizmeci, D., Fischinger, S., Collier, A.-R. Y., Suscovich, T. J., Linde, C., Broge, T. A., Mann, C. J., Amanat, F., Dayal, D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm2311 · Cited by 136

Convalescent Plasma Therapy for COVID-19: State of the Art

Focosi, D., Anderson, A. O., Tang, J. W.-T., & Tuccori, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00072-20 · Cited by 125

Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies

Golay, J., Andrea, A. E., & Cattaneo, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929895 · Cited by 130

Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses

Sievers, B. L., Chakraborty, S., Xue, Y., Gelbart, T., Gonzalez, J. C., Cassidy, A. G., Golan, Y., Prahl, M., Gaw, S. L., Arunachalam, P. S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn7842 · Cited by 111

Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets

Bye, A. P., Hoepel, W., Mitchell, J. L., Jegouic, S. M., Loureiro, S., Sage, T., Vidarsson, G., Nouta, J., Wuhrer, M., de Taeye, S. W., et al. (2021) · Blood · doi:10.1182/blood.2021011871 · Cited by 111

Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity

Yates, J. L., Ehrbar, D. J., Hunt, D., Girardin, R. C., Dupuis, A. P., Payne, A. F., Sowizral, M., Varney, S. D., Kulas, K. E., Demarest, V. L., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100329 · Cited by 104

Sialylation as an Important Regulator of Antibody Function

Vattepu, R., Sneed, S. L., & Anthony, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818736 · Cited by 104

Endothelial Cell–Activating Antibodies in COVID‐19

Shi, H., Zuo, Y., Navaz, S. A., Harbaugh, A., Hoy, C. K., Gandhi, A. A., Sule, G. J., Yalavarthi, S., Gockman, K., Madison, J. A., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42094 · Cited by 97

The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients

Luo, H., Jia, T., Chen, J., Zeng, S., Qiu, Z., Wu, S., Li, X., Lei, Y., Wang, X., Wu, W., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632814 · Cited by 97

Plasma miRNA profile at COVID-19 onset predicts severity status and mortality

Fernández-Pato, A., Virseda‐Berdices, A., Resino, S., Ryan, P., Martínez-Nieto, Ó., Pérez‐García, F., Martin‐Vicente, M., Valle‐Millares, D., Brochado‐Kith, O., Blancas, R., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2038021 · Cited by 92

A Granulocytic Signature Identifies COVID-19 and Its Severity

Vitte, J., Diallo, A. B., Boumaza, A. F., Lopez, A., Michel, M., Allardet-Servent, J., Mezouar, S., Sérémé, Y., Busnel, J., Miloud, T., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa591 · Cited by 90

SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?

Chakraborty, S., Mallajosyula, V. V. A., Tato, C. M., Tan, G. S., & Wang, T. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.014 · Cited by 90

mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine

Buhre, J. S., Pongrácz, T., Künsting, I., Lixenfeld, A. S., Wang, W., Nouta, J., Lehrian, S., Schmelter, F., Lunding, H. B., Dühring, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020844 · Cited by 90

IgG glycans in health and disease: Prediction, intervention, prognosis, and therapy

Shkunnikova, S., Mijakovac, A., Sironić, L., Hanić, M., Lauc, G., & Kavur, M. M. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108169 · Cited by 88

Decay of Fc-dependent antibody functions after mild to moderate COVID-19

Lee, W. S., Selva, K. J., Davis, S. K., Wines, B. D., Reynaldi, A., Esterbauer, R., Kelly, H. G., Haycroft, E. R., Tan, H., Juno, J. A., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100296 · Cited by 81

Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma

Wu, R., Lao, X., Chen, D., Qin, H., Mu, M., Cao, W.-J., Deng, J., Wan, C.-C., Zhan, W.-Y., Wang, J., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.11.014 · Cited by 77

The role of B cells in COVID-19 infection and vaccination

Chen, S., Guan, F., Candotti, F., Benlagha, K., Câmara, N. O. S., Herrada, A. A., James, L. K., Lei, J., Miller, H., Kubo, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988536 · Cited by 75

Finding the sweet spot: glycosylation mediated regulation of intestinal inflammation

Brazil, J. C., & Parkos, C. A. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00466-8 · Cited by 74

SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release

Junqueira, C., Crespo, Â., Ranjbar, S., Ingber, J., Parry, B., Ravid, S., Lacerda, L. B. D., Lewandrowski, M., Clark, S., Ho, F., et al. (2021) · doi:10.1101/2021.03.06.21252796 · Cited by 70

Longitudinal Characterization of Circulating Neutrophils Uncovers Distinct Phenotypes Associated with Disease Severity in Hospitalized COVID-19 Patients

LaSalle, T. J., Gonye, A. L. K., Freeman, S. S., Kapłonek, P., Gushterova, I., Kays, K. R., Manakongtreecheep, K., Tantivit, J., Rojas-López, M., Russo, B. C., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100779 · Cited by 71

COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions

Adeniji, O. S., Giron, L. B., Purwar, M., Zilberstein, N., Kulkarni, A. J., Shaikh, M. W., BALK, R. A., Moy, J. N., Forsyth, C. B., Liu, Q., et al. (2021) · mBio · doi:10.1128/mbio.00281-21 · Cited by 74

Neutrophil Extracellular Traps Contribute to COVID-19 Hyperinflammation and Humoral Autoimmunity

Torres-Ruiz, J. J., Absalón‐Aguilar, A., Nuñez‐Aguirre, M., Pérez‐Fragoso, A., Carrillo-Vázquez, D. A., Maravillas‐Montero, J. L., Mejía‐Domínguez, N. R., Llorente, L., Alcalá‐Carmona, B., Lira‐Luna, J., et al. (2021) · Cells · doi:10.3390/cells10102545 · Cited by 70

Immunoglobulin G1 Fc glycosylation as an early hallmark of severe COVID-19

Pongrácz, T., Nouta, J., Wang, W., van Meijgaarden, K. E., Linty, F., Vidarsson, G., Joosten, S. A., Ottenhoff, T. H. M., Hokke, C. H., de Vries, J. J. C., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103957 · Cited by 68

Instructing durable humoral immunity for COVID-19 and other vaccinable diseases

Bhattacharya, D. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.004 · Cited by 64

Afucosylated IgG responses in humans – structural clues to the regulation of humoral immunity

Oosterhoff, J. J., Larsen, M. D., van der Schoot, C. E., & Vidarsson, G. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.08.001 · Cited by 64

Immune responses in mildly versus critically ill COVID-19 patients

Nasrollahi, H., Talepoor, A. G., Saleh, Z., Vakili, M. E., Heydarinezhad, P., Karami, N., Noroozi, M., Meri, S., & Kalantar, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1077236 · Cited by 63

Bat ASC2 suppresses inflammasomes and ameliorates inflammatory diseases

Ahn, M., Chen, V. C.-W., Rozario, P., Ng, W. L., Kong, P. S., Sia, W. R., Kang, A. E. Z., Su, Q., Nguyen, L. H., Zhu, F., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.036 · Cited by 67

Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors

Steenhuis, M., van Mierlo, G. J., Derksen, N. I. L., Heer, P. O., Kruithof, S., Loeff, F. C., Berkhout, L. C., Linty, F., Reusken, C. B. E. M., Reimerink, J. H. J., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1285 · Cited by 63

Host Recovery from Respiratory Viral Infection

Wei, X., Narasimhan, H., Zhu, B., & Sun, J. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-040450 · Cited by 63

Afucosylated Plasmodium falciparum-specific IgG is induced by infection but not by subunit vaccination

Larsen, M. D., Lopez-Perez, M., Dickson, E. K., Ampomah, P., Ndam, N. T., Nouta, J., Koeleman, C. A. M., Ederveen, A. L. H., Mordmüller, B. G., Salanti, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26118-w · Cited by 62

Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern

Farkash, I., Feferman, T., Saban, N. C., Avraham, Y., Morgenstern, D., Mayuni, G., Barth, N., Lustig, Y., Miller, L., Shouval, D. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110114 · Cited by 60

Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection

Semmes, E. C., Miller, I. G., Wimberly, C. E., Phan, C. T., Jenks, J. A., Harnois, M. J., Berendam, S. J., Webster, H. S., Hurst, J. H., Kurtzberg, J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156827 · Cited by 60

A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike

Claireaux, M. A. F., Caniels, T. G., de Gast, M., Han, J., Guerra, D., Kerster, G., van Schaik, B. D. C., Jongejan, A., Schriek, A. I., Grobben, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32232-0 · Cited by 64

Increased in vitro neutralizing activity of SARS-CoV-2 IgA1 dimers compared to monomers and IgG

Sun, L., Kallolimath, S., Palt, R., Stiasny, K., Mayrhofer, P., Maresch, D., Eidenberger, L., & Steinkellner, H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107148118 · Cited by 59

IgG Anti–Citrullinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Cross‐Sectional Study Encompassing ~1,500 Samples

Kissel, T., Hafkenscheid, L., van Wesemael, T. J., Tamai, M., Kawashiri, S., Kawakami, A., El-Gabalawy, H. S., van Schaardenburg, D., Rantapää‐Dahlqvist, S., Wuhrer, M., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42098 · Cited by 58

Mechanisms of antibody-dependent enhancement of infectious disease

Wells, T. J., Esposito, T., Henderson, I. R., & Labzin, L. I. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01067-9 · Cited by 61

Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19

Apostolidis, S. A., Sarkar, A., Giannini, H. M., Goel, R. R., Mathew, D., Suzuki, A., Baxter, A. E., Greenplate, A. R., Alanio, C., Abdel-Hakeem, M. S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.834988 · Cited by 59

SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children

Bartsch, Y. C., Denis, K. S., Kapłonek, P., Kang, J., Lam, E. C., Burns, M. D., Farkas, E. J., Davis, J. P., Boribong, B. P., Edlow, A. G., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9237 · Cited by 58

COVID‐19 immunopathology: From acute diseases to chronic sequelae

Arish, M., Qian, W. G., Narasimhan, H., & Sun, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28122 · Cited by 55

Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms

Brown, B., Ojha, V., Fricke, I., Al-Sheboul, S. A., Imarogbe, C., Gravier, T., Green, M., Peterson, L., Koutsaroff, I. P., Demir, A. N., et al. (2023) · Vaccines · doi:10.3390/vaccines11020408 · Cited by 55

Correlates of Vaccine-Induced Protection against SARS-CoV-2

Koch, T., Mellinghoff, S. C., Shamsrizi, P., Addo, M. M., & Dahlke, C. (2021) · Vaccines · doi:10.3390/vaccines9030238 · Cited by 57

Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: new horizons in immunotherapy

Gan, M., Liu, N., Li, W., Chen, M., Bai, Z., Liu, D., & Liu, S. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02193-7 · Cited by 50

Profile of Immunoglobulin G N-Glycome in COVID-19 Patients: A Case-Control Study

Hou, H., Yang, H., Liu, P., Huang, C., Wang, M., Li, Y., Zhu, M., Wang, J., Xu, Y., Wang, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748566 · Cited by 50

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities

Chen, Y., Sun, L., Ullah, I., Beaudoin-Bussières, G., Anand, S. P., Hederman, A. P., Tolbert, W. D., Sherburn, R. T., Nguyen, D. N. P., Marchitto, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn4188 · Cited by 49

The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees

Coillie, J. V., Pongrácz, T., Rahmöller, J., Chen, H., Geyer, C. E., van Vught, L. A., Buhre, J. S., Šuštić, T., van Osch, T. L. J., Steenhuis, M., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104408 · Cited by 48

Immunity to SARS-CoV-2: Lessons Learned

FERGIE, J. E., & Srivastava, A. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654165 · Cited by 46

COVID ‐19 and plasma cells: Is there long‐lived protection?*

Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 48

COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm

Fujimura, Y., & Holland, L. Z. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03324-w · Cited by 43

Circulating multimeric immune complexes contribute to immunopathology in COVID-19

Ankerhold, J., Giese, S., Kolb, P., Maul‐Pavicic, A., Voll, R. E., Göppert, N., Ciminski, K., Kreutz, C., Lother, A., Salzer, U., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32867-z · Cited by 46

High-throughput site-specific N -glycoproteomics reveals glyco-signatures for liver disease diagnosis

Sun, Z., Fu, B., Wang, G., Zhang, L., Xu, R., Zhang, Y., & Lu, H. (2022) · National Science Review · doi:10.1093/nsr/nwac059 · Cited by 42

Altered IgG glycosylation at COVID‐19 diagnosis predicts disease severity

Vicente, M. M., Alves, I., Gaifem, J., Rodrigues, C. S., Fernandes, Â., Dias, A. M., Štambuk, J., Pribić, T., Oliveira, P., Ferreira‐da‐Silva, F., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202149491 · Cited by 45

Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome

Gresele, P., Momi, S., Marcucci, R., Ramundo, F., Stefano, V. D., & Tripodi, A. (2021) · Haematologica · doi:10.3324/haematol.2021.279289 · Cited by 41

Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?

Lu, L., Zhang, H., Zhan, M., Jiang, J., Yin, H., Dauphars, D. J., Li, S.-Y., Li, Y., & He, Y.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1859-y · Cited by 41

COVID-19 Immunobiology: Lessons Learned, New Questions Arise

Kaklamanos, A., Belogiannis, K., Skendros, P., Gorgoulis, V. G., Vlachoyiannopoulos, P. G., & Tzioufas, A. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719023 · Cited by 37

An aberrant inflammatory response in severe COVID-19

Mérad, M., Subramanian, A. K., & Wang, T. T. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.018 · Cited by 38

IgG N-glycome changes during the course of severe COVID-19: An observational study

Petrović, T., Vijay, A., Vučković, F., Trbojević‐Akmačić, I., Ollivere, B. J., Marjanović, D., Bego, T., Prnjavorac, B., Đerek, L., Markotić, A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104101 · Cited by 37

Glycosylation in SARS-CoV-2 variants: A path to infection and recovery

Aloor, A., Aradhya, R., Venugopal, P., Nair, B. G., & Suravajhala, R. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115335 · Cited by 37

Interplay between Comorbidities and Long COVID: Challenges and Multidisciplinary Approaches

Ashmawy, R., Hammouda, E. A., El‐Maradny, Y. A., Aboelsaad, I., Hussein, M., Uversky, V. N., & Redwan, E. M. M. M. (2024) · Biomolecules · doi:10.3390/biom14070835 · Cited by 35

Serum IgG4 level predicts COVID-19 related mortality

Della‐Torre, E., Lanzillotta, M., Strollo, M., Ramirez, G. A., Dagna, L., & Tresoldi, M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.09.012 · Cited by 36

The immune roadmap for understanding multi-system inflammatory syndrome in children: opportunities and challenges

Martinez, O. M., Bridges, N. D., Goldmuntz, E. A., & Pascual, V. (2020) · Nature Medicine · doi:10.1038/s41591-020-1140-9 · Cited by 34

IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma Pools

Kober, C., Manni, S., Wolff, S., Barnes, T. W., Mukherjee, S., Vogel, T., Hoenig, L., Peter, V., Hahn, A., Gerlach, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262162 · Cited by 37

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants

Strohl, W. R., Ku, Z., An, Z., Carroll, S. F., Keyt, B. A., & Strohl, L. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00529-7 · Cited by 35

Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy

Herman, J. D., Wang, C., Burke, J. S., Zur, Y., Compere, H., Kang, J., Macvicar, R., Taylor, S., Shin, S. A., Frank, I., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100811 · Cited by 34

Immunoglobulin G N-glycan markers of accelerated biological aging during chronic HIV infection

Giron, L. B., Liu, Q., Adeniji, O. S., Yin, X., Kannan, T., Ding, J., Lu, D. Y., Langan, S. J., Zhang, J., Azevedo, J. L. L. C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47279-4 · Cited by 33

Protective non-neutralizing SARS-CoV-2 monoclonal antibodies

Izadi, A., & Nordenfelt, P. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.06.003 · Cited by 36

Why Do Some People Develop Serious COVID-19 Disease After Infection, While Others Only Exhibit Mild Symptoms?

Ballow, M. C., & Haga, C. L. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.01.012 · Cited by 34

BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age

Bates, T. A., Lu, P., Kang, Y. J., Schoen, D., Thornton, M. A., McBride, S. K., Park, C., Kim, D., Messer, W. B., Curlin, M. E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111544 · Cited by 32

Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination

Tong, X., McNamara, R. P., Avendaño, M. J., Serrano, E. F., García‐Salum, T., Pardo‐Roa, C., Bertera, H. L., Chicz, T. M., Lévican, J., Poblete, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39189-8 · Cited by 38

A Case–Control Study of the 2019 Influenza Vaccine and Incidence of COVID-19 Among Healthcare Workers

Massoudi, N., & Mohit, B. (2020) · Journal of Clinical Immunology · doi:10.1007/s10875-020-00925-0 · Cited by 32

SARS-CoV-2 infection of phagocytic immune cells and COVID-19 pathology: Antibody-dependent as well as independent cell entry

Matveeva, O. V., Nechipurenko, Y. D., Lagutkin, D., Yegorov, Y. E., & Kzhyshkowska, J. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050478 · Cited by 32

Enhanced Immunomodulatory Effect of Intravenous Immunoglobulin by Fc Galactosylation and Nonfucosylation

Mimura, Y., Mimura‐Kimura, Y., Saldova, R., Rudd, P. M., & Jefferis, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818382 · Cited by 31

Immunoassay for quantification of antigen-specific IgG fucosylation

Šuštić, T., Coillie, J. V., Larsen, M. D., Derksen, N. I. L., Szittner, Z., Nouta, J., Wang, W., Damelang, T., Rebergen, I., Linty, F., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104109 · Cited by 30

Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective

Ajmeriya, S., Kumar, A., Karmakar, S., Rana, S., & Singh, H. (2022) · Journal of the Indian Institute of Science · doi:10.1007/s41745-021-00268-8 · Cited by 29

Activation of the AIM2 Receptor in Circulating Cells of Post-COVID-19 Patients With Signs of Lung Fibrosis Is Associated With the Release of IL-1α, IFN-α and TGF-β

Colarusso, C., Terlizzi, M., Maglio, A., Molino, A., Candia, C., Vitale, C., Hansbro, P. M., Vatrella, A., Pinto, A., & Sorrentino, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.934264 · Cited by 29

The role and uses of antibodies in COVID-19 infections: a living review

Scourfield, D. O., Reed, S. G., Quastel, M. N., Alderson, J., Bart, V. M. T., Crespo, A. T., Jones, R. E., Pring, E., Richter, F. C., Ahern, D., et al. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab003 · Cited by 30

Innate immune response analysis in COVID-19 and kawasaki disease reveals MIS-C predictors

Yang, C.-A., Huang, Y., & Chiang, B. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.06.009 · Cited by 28

Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial

Fish, M., Rynne, J., Jennings, A. R., Lam, C., Lamikanra, A., Ratcliff, J., Trevelin, S. C., Timms, E. M., Jiriha, J., Tosi, I., et al. (2022) · Intensive Care Medicine · doi:10.1007/s00134-022-06869-w · Cited by 28

High Anti-Leishmania IgG Antibody Levels Are Associated With Severity of Mucosal Leishmaniasis

de Lima, C. M. F., Magalhães, A. S., Costa, R. S., Barreto, C. C., Machado, P. R. L., Carvalho, E. M., Lessa, M. M., & Carvalho, L. P. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.652956 · Cited by 27

Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors

Li, S., McCraw, A. J., Gardner, R. A., Spencer, D. I. R., Karagiannis, S. N., & Wagner, G. K. (2021) · Antibodies · doi:10.3390/antib10040044 · Cited by 27

Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity

Chakraborty, S., González, J. C., Sievers, B. L., Mallajosyula, V. V. A., Chakraborty, S., Dubey, M., Ashraf, U., Cheng, B. Y.-L., Kathale, N. D., Tran, K. Q. T., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm7853 · Cited by 137

Immunoglobulin G1 Fc glycosylation as an early hallmark of severe COVID-19

Pongrácz, T., Nouta, J., Wang, W., van Meijgaarden, K. E., Linty, F., Vidarsson, G., Joosten, S. A., Ottenhoff, T. H. M., Hokke, C. H., de Vries, J. J. C., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103957 · Cited by 68

Altered Spike Immunoglobulin G Fc N-Linked Glycans Are Associated With Hyperinflammatory State in Adult Coronavirus Disease 2019 and Multisystem Inflammatory Syndrome in Children

Sherman, J. D., Karmali, V., Kumar, B., Simon, T. W., Bechnak, S., Panjwani, A., Ciric, C. R., Wang, D., Huerta, C., Johnson, B. E., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae626 · Cited by 1

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

Larsen, M. D., de Graaf, E. L., Sonneveld, M. E., Plomp, H. R., Nouta, J., Hoepel, W., Chen, H.-J., Linty, F., Visser, R., Brinkhaus, M., et al. (2021) · Science · doi:10.1126/science.abc8378 · Cited by 408

Altered spike IgG Fc N-linked glycans are associated with hyperinflammatory state in adult COVID and Multisystem Inflammatory Syndrome in ChildrenPreprint

Sherman, J. D., Karmali, V., Kumar, B., Simon, T. W., Bechnak, S., Panjwani, A., Ciric, C. R., Wang, D., Huerta, C., Johnson, B. E., et al. (2024) · medRxiv · doi:10.1101/2024.07.14.24310381